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Elevated hepatic synthesis of fatty acids and triglyc-
erides, driven by hyperactivation of the SREBP-1c
transcription factor, has been implicated as a causal
feature of metabolic syndrome. SREBP-1c activation
requires the proteolytic maturation of the endo-
plasmic-reticulum-bound precursor to the active,
nuclear transcription factor, which is stimulated by
feeding and insulin signaling. Here, we show that
feeding and insulin stimulate the hepatic expression
of PASK. We also demonstrate, using genetic and
pharmacological approaches, that PASK is required
for the proteolytic maturation of SREBP-1c in
cultured cells and in the mouse and rat liver. Inhibi-
tion of PASK improves lipid and glucose metabolism
in dietary animal models of obesity and dyslipidemia.
Administration of a PASK inhibitor decreases hepatic
expression of lipogenic SREBP-1c target genes, de-
creases serum triglycerides, and partially reverses
insulin resistance. While the signaling network that
controls SREBP-1c activation is complex, we pro-
pose that PASK is an important componentwith ther-
apeutic potential.
INTRODUCTION
Excessive synthesis and storage of lipids is a prominent feature
of the current epidemic of metabolic disorders, including
obesity, diabetes, and their comorbidities. Upon feeding, fatty
acids and triglycerides are synthesized primarily in the liver and
adipose tissue in response to insulin signaling, and then are
either stored locally or exported to other tissues for use in ATP
production. The Sterol Regulatory Element Binding Protein
(SREBP-1c) transcription factor is a principal regulator of lipo-
genesis in these two tissues (Horton et al., 2002; Rosen et al.,
2000). Upon activation, SREBP-1c stimulates expression of the
entire enzymatic pathway that converts acetate to fatty acids
and their esterification to triacylglycerol (TAG) (Horton et al.,
2003). Hyperactivation of SREBP-1c has been implicated in242 Cell Reports 8, 242–255, July 10, 2014 ª2014 The Authorspromoting pathological fat synthesis and driving features of
metabolic syndrome, including hepatic lipid accumulation (or
steatosis), dyslipidemia, and insulin resistance (Brown andGold-
stein, 2008).
Although it is often pathological in modern humans, SREBP-
1c activation in response to feeding is a normal physiological
response that enables the storage of excess energy in the sta-
ble and compact TAG form. SREBP-1c activation by feeding
occurs predominantly in response to insulin, which acts at mul-
tiple regulatory steps. Transcription of the SREBP-1c mRNA is
strongly induced by insulin via a mechanism involving the LXR
transcription factor (Chen et al., 2004; DeBose-Boyd et al.,
2001; Repa et al., 2000; Schultz et al., 2000; Yoshikawa
et al., 2001) and SREBP-1c autoregulation (Amemiya-Kudo
et al., 2000; Chen et al., 2004). Insulin also acts, through
GSK-3b inhibition and potentially through Lipin1 phosphoryla-
tion, to extend the otherwise very short half-life of active
SREBP-1c (Harris et al., 2007; Pe´terfy et al., 2010; Peterson
et al., 2011; Sundqvist et al., 2005). One of the most important
mechanisms underlying SREBP-1c activation by insulin
signaling, however, is the proteolytic maturation of the endo-
plasmic reticulum (ER) membrane-embedded SREBP-1c
precursor into the active and nuclear mature SREBP-1c tran-
scription factor (Hegarty et al., 2005).
Analogous to what has been described for its better-charac-
terized paralog, SREBP-2, maturation of SREBP-1c is thought
to occur through the regulated translocation of the precursor
to the Golgi, where it is cleaved sequentially by two proteases,
liberating the mature form from its two transmembrane seg-
ments (Horton et al., 2002; Raghow et al., 2008). The regulatory
pathway linking insulin and SREBP-1c maturation is incom-
pletely understood, but has been shown to require the canonical
PI3K/Akt pathway (Krycer et al., 2010; Yellaturu et al., 2009a).
More recently, evidence has shown that insulin-responsive
SREBP-1c activation also requires the mechanistic Target of
Rapamycin Complex 1 (mTORC1) (Du¨vel et al., 2010; Li et al.,
2010; Porstmann et al., 2008). Although part of the effect of in-
sulin/Akt on SREBP-1c maturation appears to depend on the
regulation of INSIG2 gene expression (Yecies et al., 2011; Yell-
aturu et al., 2009b), the mechanism(s) underlying Akt/mTORC1’s
effect on SREBP-1c proteolytic maturation have not been
identified.
PAS kinase (PASK) is an evolutionarily conserved serine/thre-
onine kinase, and we previously proposed that it plays an impor-
tant role as a nutrient-responsive metabolic regulator (Hao and
Rutter, 2008). Mice lacking the PASK gene (Pask/) exhibit
a number of tissue-specific metabolic abnormalities, but the
most profound phenotype observed to date is decreased sus-
ceptibility to hepatic lipid infiltration in animals challenged with
a high-fat diet (HFD) (Hao et al., 2007). Hepatic steatosis is
now recognized to be a common and devastating component
of metabolic syndrome (Cohen et al., 2011). However, the mole-
cularmechanisms underlying hepatic steatosis are unknown and
no therapies are currently approved for its treatment. Given the
profound Pask/ phenotype, the importance of this process in
human disease, and the potential to discover new therapeutic
targets, we sought to identify the mechanism whereby PASK
regulates hepatic lipid metabolism.
RESULTS
PASK Stimulates Hepatic Lipogenesis by Activating
SREBP-1c
Since Pask/ mice are protected from HFD-induced hepatic
steatosis, we initially compared the hepatic transcriptional pro-
files of lipogenic genes from Pask/ and wild-type (WT) mice
in both fasted and fed states. The expression levels of the genes
encoding glycerol-3-phosphate acyltransferase (Gpat1), fatty
acid synthase (Fasn), and acetyl-coA carboxylase (Acc1) were
all similarly low in the fasted state in WT and Pask/ livers (Fig-
ures 1A–1C). Although expression of these genes increased sub-
stantially in WT mice upon feeding, this induction was blunted in
Pask/ mice (Figures 1A–1C). This feeding-dependent effect
led us to test the expression of these same genes in fasted
and fed mice that were maintained on a normal chow diet
(NCD). As with the HFD, the expression levels of the lipogenic
genes were similar in WT and Pask/ mice in the fasted state.
Refeeding for 6 or 8 hr, however, significantly increased the
expression of Gpat1, Fasn, and Acc1 in WT liver, and this in-
crease was absent or blunted in Pask/ mice (Figures 1D–1F).
We previously observed that PASK activity was nutrient
responsive in cultured cells. This led us to hypothesize that
PASK expression or activity might also be stimulated in the liver
upon feeding, which might then be required for NCD-induced
lipogenic gene expression. We therefore measured the hepatic
Pask mRNA levels in fasted and fed mice. HFD-fed WT mice
showed an increase inPask expression upon feeding (Figure 1G).
An even larger increase was observed in NCD-fed animals upon
2 hr of feeding following a fast (Figure 1H). Interestingly, by 6 hr of
feeding, the Pask mRNA abundance had returned to the fasted
level. This acute hepatic induction of Pask by feeding is likely
to be a cell-autonomous response to insulin, as we observed
induction of Pask mRNA by insulin in WT primary hepatocytes
(Figure 1I).
To further investigate the mechanisms whereby PASK defi-
ciency led to reduced expression of lipogenic genes, we em-
ployed HepG2 human hepatoma cells treated with insulin, which
is a major hormonal mediator of the response of lipogenic gene
expression to feeding. PASK knockdown by three different small
interfering RNAs (siRNAs; denoted as siA, siB, and siC) in HepG2cells (Figure 2A) caused decreased expression of GPAT1 and
SCD1 upon insulin treatment (Figure 2B). Unlike the liver, how-
ever, HepG2 cells seem to have a basal level of lipogenic gene
expression that is PASK dependent. In the absence of insulin,
PASK knockdown caused decreased expression of GPAT1
and SCD1 in HepG2 cells (Figure S1A). The fact that acute
PASK knockdown in HepG2 cells recapitulates the regulation
of gene expression observed in vivo in Pask/ liver suggests a
direct role for PASK in regulating lipogenesis.
To determine whether this change in mRNA abundance is due
to transcriptional control, we examined the effects of PASK
knockdown on luciferase activity from a reporter gene driven
by the promoter of either GPAT1 (Yoshida et al., 2009) or
SCD1 (Bene´ et al., 2001). As shown in Figures S1B and S1C,
PASK knockdown decreased the activity of both the GPAT1
and SCD1 promoters. Because SREBP-1c is one of the major
feeding- and insulin-responsive regulators of GPAT1, SCD1,
and the other components of the fatty acid and TAG biosynthetic
pathway, we analyzed the effects ofPASK knockdown on a lucif-
erase reporter gene containing isolated SREBP-binding sites
(Dooley et al., 1998). PASK knockdown caused a modest reduc-
tion in SREBP activity in serum-starved conditions, which
became more pronounced upon insulin treatment (Figure 2C).
One potential explanation for the loss of basal and insulin-stim-
ulated SREBP-1 activation upon PASK knockdown is that the
Akt/mTORC1 pathway, which is required for SREBP-1 activa-
tion, is impaired by PASK knockdown. However, the phosphor-
ylation states of Akt and S6K (indicative of Akt and mTORC1
activity, respectively) were both unchanged by PASK knock-
down (Figure 2D), demonstrating that the effects of PASK on
SREBP-1 activation occur without effects on Akt and mTORC1
activity. Over many independent experiments, PASK knock-
down with each of these three different siRNAs caused a sig-
nificant impairment in the fold-induction of SREBP activity by
insulin (siA: n = 15, p = 0.003; siB: n = 16, p < 0.0001; siC: n =
9, p = 0.01). Taken together, these data support a model wherein
SREBP-1c is a major mediator of the transcriptional effects of
PASK on the regulation of lipid biosynthesis, and PASK is
required for the full effect of insulin on SREBP-1c induction.
PASK Promotes SREBP-1 Maturation
SREBP-1c is profoundly regulated by insulin atmultiple levels, as
described above. Given the requirement of PASK for the normal
regulation of SREBP-1c, we first assessed whether it is also
required for its proteolytic maturation. We examined this directly
by monitoring the levels of the precursor and mature forms of
SREBP-1c. We also examined the maturation of SREBP-1a,
which is derived from the same gene as SREBP-1c but is the
product of an alternative promoter (Hua et al., 1995). Treatment
of cells with either one of two PASK-specific siRNAs (siA and
siB), but not the control siRNA, blunted the insulin-responsive
maturation of SREBP-1a and SREBP-1c (Figures 3A and S2A).
As before, PASK knockdown impaired SREBP-1 processing,
but had no effect on Akt or S6K phosphorylation (Figures 3A
and S2A). The insulin-responsive proteolytic maturation of
SREBP-1c is also observed upon feeding in rodent liver. In WT
mice maintained on an NCD, we observed a significant increase
in the abundance of mature SREBP-1c in the fed state relative toCell Reports 8, 242–255, July 10, 2014 ª2014 The Authors 243
Figure 1. PASK Is Feeding Induced and Is Required for Normal Feeding-Dependent Induction of Lipogenic Gene Expression.
(A–H) WT and Pask/ (KO) mice on the C57/BL6J background were maintained on a 60% HFD (A–C and G) for 8 weeks (n R 4) or an NCD (D–F and H) for
12 weeks (n = 3). Before harvesting, mice were fasted for 24 hr or fasted for 24 hr and refed either an HFD for 12 hr (A–C and G) or an NCD for the indicated times
(D–F and H). Livers were harvested and themRNA levels of the indicated geneswere measured by quantitative RT-PCR (qRT-PCR) and normalized toCyclophilin
A mRNA. Data shown are the average ± SEM, with the ‘‘WT fasted’’ value set as one.
(I) Rat primary hepatocytes were serum starved overnight and incubated with 25 nM insulin for the indicated times. PaskmRNA was measured by qRT-PCR and
normalized to r36B4. Data shown are the average of n = 3 ± SEM. The value of the 0 hr group was set as one.
See also Tables S1 and S2.the fasted state (Figure 3B). This induction was severely blunted
in Pask/ mice (Figure 3B). Feeding-induced maturation of
SREBP-1c was also observed in WT mice maintained on an
HFD, but was essentially absent in Pask/ mice (Figure 3C).
The INSIG proteins are negative regulators of SREBP-1
maturation and are regulated at many levels, including transcrip-
tion and mRNA stability (Gong et al., 2006; Yabe et al., 2002,
2003; Yang et al., 2002; Yellaturu et al., 2009b). Alterations
in the expression of Insig2a have been specifically implicated
in mediating the effects of insulin on SREBP-1c processing in
hepatic tissue (Yabe et al., 2003; Yecies et al., 2011; Yellaturu244 Cell Reports 8, 242–255, July 10, 2014 ª2014 The Authorset al., 2009b). However, it appears that the effects of PASK
knockdown on SREBP-1c maturation are not due to altered
INSIG2 expression, as this gene is not induced in HepG2 cells
upon PASK knockdown (Figure 3D). In fact, INSIG2 expression
actually is decreased by two out of three PASK-targeted
siRNAs, perhaps as a compensatory mechanism that the cell
employs to attempt to restore SREBP-1c maturation. We
measured the Insig1, Insig2a and Insig2b mRNAs in WT and
Pask/ liver under fed and fasted conditions in mice maintained
on either the NCD or HFD. Again, under no condition did we
observe an increase in Insig2a expression (Figures 3E and 3F).
Figure 2. PASK Is Required for Full SREBP-1 Activity
(A) HepG2 cells were treated with scrambled or PASK-specific siRNA (siA, siB, or siC) and subjected to immunoblot for PASK.
(B)PASK-silenced HepG2 cells were serum starved overnight and stimulatedwith 100 nM insulin for 6 hr. ThemRNA levels of the indicated genes weremeasured
by qRT-PCR and normalized to Tubulin mRNA levels. Data shown are the average of n = 3 ± SEM, with the Scr value set as one.
(C) PASK-silenced HepG2 cells were transfected with SRE-Luc reporter, serum starved overnight, and stimulated with 100 nM insulin for 6 hr as indicated.
Firefly and Renilla luciferase were assayed using the Dual-Reporter Luciferase Assay System. Data shown are the average of n = 3 ± SD, with the ‘‘scrins’’ value
set as one.
(D) Following the luciferase assay, cell lysates from (C) were subjected to immunoblot to determine the phosphorylation state and abundance of the indicated
proteins.
See also Figure S1.We also did not observe an increase in expression of the other
INSIG isoforms, Insig1 and Insig2b, in Pask/ mice (Figures
S2B and S2C). We therefore conclude that PASK promotes
SREBP-1 maturation, but does so independently of effects on
INSIG gene expression.
We also addressed whether PASK might regulate the stability
or transcriptional activation potential of mature, nuclear
SREBP-1 (other known mechanisms of SREBP-1 control). We
expressed a truncated form of SREBP-1a, or GFP as a control,
and asked whether PASK knockdown had any effect on SRE-
driven luciferase activity. As shown in Figure 3G, PASK knock-
down with siB in GFP-control cells led to decreased luciferase
activity in both the presence and absence of insulin. Expression
of the mature SREBP-1a, however, caused luciferase activity to
become completely insensitive to PASK knockdown (Figure 3G).
We were concerned that expression of this ectopic transcription
factor might have overwhelmed the PASK regulatory system and
the PASK insensitivity was due to an overexpression artifact.
Therefore, we expressed the full-length, precursor SREBP-1a
and found that PASK knockdown retained the ability to suppress
luciferase activity (Figure 3G). To achieve a similar transcriptional
response, we expressed much more full-length SREBP-1a,
which requires processing for activation. In spite of this, the
full-length SREBP-1a was regulated by PASK, whereasthe mature form of SREBP-1a was not. We thus conclude that
the activity of the nuclear, mature form is resistant to PASK
knockdown. PASK knockdown with siA, which is more effective
at silencing PASK and decreasing SREBP-1 activity (Figure 2),
followed the same pattern, although PASK knockdown still
caused a small but significant decrease in SREBP activity even
when the mature SREBP-1a was expressed (Figure S2D).
This was likely due to endogenous SREBP-1, whose activity
remained PASK dependent. As before, the activity of over-
expressed full-length, precursor SREBP-1a was PASK depen-
dent. The loss of SREBP-1 activity upon PASK knockdown
again occurred in the absence of any effect on insulin or
mTORC1 signaling (Figures 3G and S2D). We initially attempted
the above experiment with SREBP-1c, which has much weaker
transcriptional activation potential than SREBP-1a (Shimano
et al., 1997a), but we were unable to express enough full-length
precursor SREBP-1c to achieve comparable luciferase activity.
This technical issue prevented a rigorous interpretation of the
analogous experiment with SREBP-1c.
Finally, we sought to address whether the transcriptional
control of SREBP-1c might depend upon PASK. This is a difficult
question to answer, however, because SREBP-1c stimulates the
expression of its own promoter (Amemiya-Kudo et al., 2000;
Chen et al., 2004). Therefore, posttranscriptional effects onCell Reports 8, 242–255, July 10, 2014 ª2014 The Authors 245
Figure 3. PASK Promotes SREBP-1 Maturation
(A) PASK-silenced HepG2 cells expressing GFP, 3xFlag-tagged precursor SREBP-1a, or SREBP-1c were serum starved overnight and stimulated with 100 nM
insulin for 6 hr as indicated. Whole-cell lysates and nuclear extracts were subjected to immunoblot to determine the phosphorylation state and abundance of the
indicated proteins.
(B and C) Livers were harvested fromWT or Pask/ (KO) mice maintained on an NCD (B) or HFD (C) as described in Figure 1, except that mice were refed for 8 hr
(B) or 6 hr (C). Whole-liver lysates and nuclear extracts were subjected to immunoblot to determine the abundance of the indicated proteins.
(legend continued on next page)
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SREBP-1c activity will indirectly result in alterations to the
SREBP-1c mRNA level. As expected, we observed that
the SREBP-1c mRNA was decreased in Pask/ liver (Table
S1) in parallel with the decrease in SREBP-1c target genes
described above (Figure 1). Inhibition of PASK caused a modest
reduction in the activity of the mSREBP-1c promoter as deter-
mined using a luciferase reporter assay in rat primary hepato-
cytes stimulated with insulin (Figure S2E). This effect of PASK
on promoter activity was dependent on SREBP-1 autoregula-
tion, however, as a promoter in which the SREBP-binding site
had been mutated showed no response to PASK inhibition (Fig-
ure S2E). We also observed amodest decrease in the level of the
SREBP-1a mRNA (Table S1), but this is unlikely to be a major
contributor to the expression of lipogenic genes in the liver
because it is expressed at a much lower level than SREBP-1c
(Shimomura et al., 1997). We observed no consistent alteration
in the expression of SREBP-2 or its target genes in Pask/
mice maintained on either the NCD or HFD (Tables S1 and S2).
Taken together, these experiments suggest that in the absence
of transcriptional control, PASK regulates the posttranslational
maturation of SREBP-1 in response to insulin. However, we
cannot exclude the possibility that PASK might also regulate
SREBP-1c transcriptionally.
Pharmacological Inhibition of PASK Leads to Decreased
SREBP-1 Activity
To facilitate the assessment of the importance of PASK for regu-
lating SREBP-1c activity and lipid homeostasis in vivo, we devel-
oped a series of PASK inhibitors. Among them, we selected for
further study two highly selective and potent inhibitors: BioE-
1115 and BioE-1197 (Figure 4A). To assess their in vitro speci-
ficity, we measured the activity of PASK and 50 other protein
kinases, selected to represent the breadth of the human kinase
family, in the presence of BioE-1115 or BioE-1197. As shown
in Figure 4B, BioE-1115 specifically inhibits PASK, with an IC50
of 4 nM. Second to PASK, casein kinase 2a was the kinase
most potently inhibited by BioE-1115, having an IC50 of
10 mM. This is interesting because of the unexpected structural
similarities between the kinase domains of PASK and casein
kinase 2 (Kikani et al., 2010). In spite of this similarity, however,
BioE-1115 was roughly 2,500-fold more potent as an inhibitor
of PASK than of casein kinase 2a2 (Figure 4B). BioE-1197
showed similar specificity for PASK versus the same 50 protein
kinases. As shown in Figure S3A, even when we used an
extremely high concentration of BioE-1197 (100 mM), the
majority of the 50 kinases were either unaffected or only
modestly inhibited. PASK, however, was essentially completely
inactivated and eight other kinases were also substantially in-
hibited. In full dose-response inhibition curves for these nine
BioE-1197-sensitive kinases, all but two were inhibited poorly,(D) HepG2 cells were treated and human INSIG2mRNA levels were analyzed as i
as one.
(E and F) Mouse Insig2a mRNA levels in livers of mice (from B and C) fed an NC
average of n = 3 ± SEM, with the ‘‘WT fasted’’ value set as one.
(G) Left: SRE-Luc activity was measured in PASK-silenced HepG2 cells expressin
the luciferase assay, cell lysates were subjected to immunoblot to determine the
See also Figure S2.with an IC50 of >50 mM (Figure S3B). Similar to what we observed
with BioE-1115, casein kinase 2a was inhibited by BioE-1197,
but with a 1,000-fold higher IC50 compared with PASK (Fig-
ure S3B). For subsequent use as a control, we also synthesized
an enantiomer of BioE-1197, which was100-fold less potent at
inhibiting PASK in vitro (IC50 = 870 nM; Figure 4C).
We next examined the efficacy of BioE-1115, BioE-1197, and
BioE-1428 for PASK inhibition in cultured cells. We tested this by
virtue of the ability of PASK to autophosphorylate at Thr-307,
which we have demonstrated to be solely dependent upon
PASK activity (Figure S3C). In the presence of either BioE-1115
or BioE-1197, we observed a dose-dependent loss of PASK
phosphorylation, with an IC50 of1 mM (Figure 4D). As expected,
the enantiomer BioE-1428 was less effective at PASK inhibition
in cells, with an IC50 of >10 mM (Figure 4D).
Having validated that BioE-1115 and BioE-1197 are potent
and specific inhibitors of PASK, we were then able to use them
to probe the acute effects of PASK inhibition. Specifically, we
sought to determine whether pharmacological PASK inhibition,
like PASK knockdown and PASK deletion, leads to impaired
SREBP-1 activity. We measured SRE-driven luciferase activity
in the presence of varying concentrations of BioE-1115 and
BioE-1197. We observed a significant reduction in SREBP acti-
vity at all concentrations above 10 mM for BioE-1115 and 3 mM
for BioE-1197 (Figure 5A), without any observable effects on
cell morphology or growth rate. This effect is likely to be specific
for PASK inhibition, because treatment of cells with BioE-1428
caused only a modest reduction of SREBP activity even at the
highest concentration tested, 50 mM (Figure S3D). As with
PASK knockdown, neither compound impaired the phosphory-
lation of Akt or S6K in response to insulin (Figures 5B and
S3E), demonstrating again that the loss of SREBP-1 activity is
not due to a loss of canonical insulin signaling.
If BioE-1115 and BioE-1197 suppress SREBP-1 activity
through inhibition of PASK, they should act by blocking
SREBP-1 proteolytic activation, as was observed with PASK
knockdown in cells and in the liver of Pask/ mice. Both BioE-
1115 and BioE-1197 suppressed SREBP-1c maturation, as
evidenced by a decrease in the mature/precursor SREBP-1c
ratio, at 30 and 50 mM concentrations (Figures 5C and S3F). In
contrast, BioE-1428 had no effect at 30 mM and the effect at
50 mM was weaker than observed with BioE-1197 (Figure S3F).
When quantified over five independent experiments, BioE-
1197 was significantly more efficacious at suppressing
SREBP-1c maturation than BioE-1428 (Figure S3G). In sum-
mary, both PASK knockdown and pharmacological inhibition
led to impaired SREBP-1 activity, and both manipulations
impacted the maturation step. These complementary data
support the hypothesis that PASK is required for the normal
maturation and activation of SREBP-1.n Figure 2B. Data shown are the average of n = 3 ± SEM, with the Scr value set
D (E) or HFD (F) were measured as described in Figure 1. Data shown are the
g GFP or mature or precursor SREBP-1a along with SRE-Luc. Right: following
phosphorylation state and abundance of the indicated proteins.
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Figure 4. BioE-1115 and BioE-1197 are PASK-Specific Inhibitors
(A) Chemical structures of BioE-1115, BioE-1197, and BioE-1428.
(B) The activity of the indicated kinases was measured in the presence of either vehicle or BioE-1115, and IC50 values were measured.
(C) Purified PASK protein kinase activity was assayed as in (B) in the presence of the indicated concentrations of BioE-1197, BioE-1428, or BioE-1115, and the
percentage of vehicle-treated activity was determined as indicated.
(D) HEK293 cells expressing a Flag-tagged PASK protein were treated with the indicated concentrations of BioE-1115, BioE-1197, or BioE-1428. PASK activity
was analyzed by ELISA with both phospho-Akt substrate antibody and pan-PASK antibody. The quantitated phospho/total PASK signal is plotted ± SEM.
See also Figure S3.We next tested whether PASK inhibition would lead to a
decrease in the synthesis of fatty acids and triglycerides, as
would be predicted based on the impairment in SREBP-1c
activity. We measured the incorporation of 14C from 14C-acetate
into lipid soluble material, which is primarily triglyceride under
these conditions. Treatment with 10 mM BioE-1197 caused a
60% decrease in 14C incorporation into lipids (Figure 5D),
suggesting that the impaired SREBP-1 activity is manifest at
the level of lipogenesis.
Rat primary hepatocytes have been used extensively in
studies of insulin-responsive SREBP-1c activation and lipo-
genesis. We previously observed that PASK gene expression
was stimulated by insulin (Figure 1I). Therefore, we explored
whether PASK inhibition would have any effect on the insulin-
responsive expression of SREBP-1c target genes in these cells.
Primary hepatocytes were isolated, plated, pretreated with
DMSO or BioE-1197 for 16 hr, and then stimulated with either248 Cell Reports 8, 242–255, July 10, 2014 ª2014 The Authorsinsulin or vehicle over a 12 hr time course. Insulin caused a sig-
nificant increase in the mRNAs encoding fatty acid synthase and
glucokinase (Fasn and Gck, respectively; Figures 5E and 5F).
This increase was either blunted or abolished by the PASK inhib-
itor. In these cells, BioE-1197 caused a significant decrease in
the mRNA encoding SREBP-1c under both basal and insulin-
stimulated conditions (Figure 5G). Finally, we measured the
incorporation of 14C from 14C-acetate into lipids. Insulin caused
a significant increase in lipogenesis in vehicle-treated hepato-
cytes, which was completely abolished by treatment with
BioE-1197 (Figure 5H).
PASK Inhibition Reduces SREBP-1c Activity and
Hypertriglyceridemia in Rodents
We previously observed that PASK deficiency in mice leads to
protection against many of the pathological effects of an HFD
(Hao et al., 2007). Most prominently, in the previous study we
found that Pask/ mice were protected from the severe diet-
induced hepatic steatosis observed in WT mice. This lipid
phenotype was accompanied by a decrease in the expression
of the lipogenic program driven by SREBP-1c (Figure 1).
Because we conducted these studies using a constitutively
deleted allele of PASK, however, we were concerned that this
phenotype might be due to adaptation or a developmental
abnormality. Therefore, we initiated studies to address the
effects of acute inhibition of PASK in adult animal models of
metabolic disease. These studies were conducted with BioE-
1115 due to the more favorable in vivo pharmacological and
pharmacokinetic properties of this PASK inhibitor relative to
BioE-1197 (Figure S4A).
WT Sprague-Dawley (SD) rats at 12 weeks of age were fed for
2 weeks with either an NCD or a high-fructose diet (HFrD), which
is known to promote dyslipidemia and insulin resistance (Hwang
et al., 1987). Those fed the HFrD were then orally dosed with
vehicle or a range of doses of BioE-1115 once a day for
1 week. Following this 1-week treatment, we harvested livers
from these rats after they were refed, and examined the mRNA
levels of SREBP-1c target genes. As expected, the SREBP-1c
target genes were upregulated in animals fed the HFrD relative
to control (Figures 6A and S4B–S4D). Among the HFrD group,
rats treated with either 1 or 3 mg BioE-1115 per kilogram of
body weight (mg/kg) showed no difference from vehicle-treated
rats. Those treatedwith 10, 30, and100mg/kg, however, showed
a dose-dependent suppression of the expression ofGpat1, Fasn
(Figure 6A), and all other SREBP-1c target genes analyzed (Fig-
ures S4B–S4D). SREBP-1 maturation in the liver was also sup-
pressed in BioE-1115-treated rats at these three doses (Fig-
ure 6B), which is consistent with what we observed in Pask/
mouse liver. However, the SREBP-2 target genes did not follow
this pattern consistently (Figures S4E–S4I). In fact, HMG-CoA
synthase1andSREBP-2 itself both followed theopposite pattern
(Figures S4E and S4J), being induced in a dose-dependent
manner by BioE-1115. This is particularly intriguing given that
mice lacking SREBP-1 frequently die in utero, but those that sur-
vive exhibit elevated expression ofSREBP-2 and its target genes,
implying some sort of compensatory mechanism between the
two transcription factors (Shimano et al., 1997b). One SREBP-2
target gene, that encoding HMG-CoA reductase, was signifi-
cantly decreased in BioE-1197-treated animals (Figure S4F).
Interestingly, this is the one SREBP-2 target gene that was also
significantly underexpressed in Pask/ mice (Table S2). Both
SREBP-1c and SREBP-1a mRNA were modestly decreased at
the highest doses of BioE-1115 (Figures S4K and S4L).
In addition to the marked change in SREBP-1c target gene
expression, we also observed a reversal of the dyslipidemic
features associated with an HFrD, as BioE-1115 treatment
caused a decrease in hepatic TAG (Figure 6C). Similarly, serum
TAG was also decreased in a dose-dependent manner by
BioE-1115 administration (Figure 6D), whereas serum choles-
terol was basically unaffected (Figure 6E). Due to the normali-
zation of triglyceride concentrations, we speculated that
BioE-1115 might have salutary effects on glucose homeostasis
as well. Indeed, the PASK inhibitor caused a significant decrease
in serum glucose (Figure 6F). This drop in glucose levels was
almost certainly a consequence of increased insulin sensitivityrather than increased insulin secretion, as serum insulin levels
were slightly lower (rather than higher) in drug-treated animals
(Figure 6G). A calculated measure of insulin resistance, termed
homeostasis model assessment-estimated insulin resistance
(HOMA-IR), was decreased in a dose-dependent manner by
BioE-1115 administration (Figure 6H). Neither dose of BioE-
1115 caused a significant change in either liver weight or body
weight (Figures 6I and 6J), suggesting that the effects on lipid
and glucose homeostasis were not due to overt toxicity.
We next performed a study of similar design except that the
HFrD-fed rats were treated for 90 days with either vehicle or
BioE-1115. The effect on SREBP-1c target gene expression
was enhanced with the longer treatment time. At 3 mg/kg
BioE-1115, expression of both Fasn and Acc1 was significantly
suppressed by PASK inhibition, and at 10, 30, and 100 mg/kg,
expression of these genes was restored to that in NCD-fed
animals (Figure S5A). The effect on SREBP-1c activity appears
to be specific for the liver, as there were no significant differ-
ences in the expression of SREBP-1c or its target genes in
abdominal fat (Figure S6A) or in gastrocnemius muscle (Fig-
ure S6B) upon BioE-1115 treatment. After 90 days of treatment
and at the interim time point of 45 days, we observed a signifi-
cant dose-responsive decrease in serum triglycerides (Figures
S5B and S5C). As in the shorter dosing period, BioE-1115
decreased serum glucose levels as measured by glycated
hemoglobin (HbA1c), which is a measure of chronic glycemia
(Figures S5D and S5E). After both 51 and 90 days of dosing,
therewas no drug-dependent difference in bodyweight between
any of the vehicle or treatment groups (Figures S5F and S5G).
DISCUSSION
The regulation of SREBP-1c is complex in terms of both the
regulatory stimuli involved and how these stimuli impinge upon
SREBP-1c activity (Raghow et al., 2008). The most widely stud-
ied and understood stimulus that promotes SREBP-1c activation
is insulin, and various components of its downstream signaling
pathway, including Akt and mTOR, have been implicated (Jeon
and Osborne, 2012). These related mechanisms combine to
elicit a profound activation of SREBP-1c in response to feeding.
We show herein that PASK is transcriptionally induced by
feeding in vivo in the liver and is also induced in a cell-autono-
mous manner by insulin in primary hepatocytes. This induction
appears to be related to SREBP-1c activation, as PASK is
required for normal feeding and insulin-responsive SREBP-1c
activity. Inhibition of PASK also impairs insulin-responsive lipid
biosynthesis, which is driven by SREBP-1c. We demonstrated
this requirement for PASK in SREBP-1c activation in four model
systems and by using three distinct modalities to block PASK
activity. SREBP-1c-driven transcription is impaired by genetic
deletion of PASK in mice fed either an NCD or HFD, pharmaco-
logical inhibition and siRNA-mediated knockdown in cultured
HepG2 cells, and pharmacological inhibition in both rat primary
hepatocytes and HFrD-fed rats. Not only do these disparate
manipulations cause the same physiological effect, they also
appear to act via the same biochemical mechanism. This pro-
vides a compelling argument that PASK is an important regulator
of SREBP-1c activation.Cell Reports 8, 242–255, July 10, 2014 ª2014 The Authors 249
Figure 5. Pharmacological Inhibition of PASK Suppresses SREBP-1 Activation
(A) SRE-Luc activity wasmeasured in HepG2 cells treated overnight with vehicle or the indicated doses of BioE-1115 or BioE-1197 followed by 100 nM insulin for
6 hr. Data are normalized to vehicle-treated samples and shown as the average of n = 3 ± SD.
(B) HepG2 cells were treated as in (A). Cell lysates were subjected to immunoblot to determine the phosphorylation state and abundance of the indicated proteins.
(C) HepG2 cells were infected as in Figure 3A and treated with PASK inhibitors and insulin as in (A). Whole-cell lysates and nuclear extracts were subjected to
immunoblot to determine the abundance of indicated proteins.
(D) 14C-acetate incorporation into lipid was measured in BioE-1197-treated HepG2 cells and normalized to the total protein in the lysate. Data shown are the
average of n = 3 ± SD.
(legend continued on next page)
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Insulin regulates SREBP-1c at almost every level of its expres-
sion and stability. Expression of the SREBF-1 gene is robustly
stimulated by insulin (Raghow et al., 2008). The precursor
SREBP-1c protein is synthesized in a latent, inactive form that
is embedded in the ER membrane. Upon insulin stimulation,
SREBP-1c translocates to the Golgi, where the protein en-
counters two proteases that cleave it to release an N-terminal
fragment that is competent to bind DNA and activate gene
expression. SREBP-1c maturation is controlled by two asso-
ciated proteins, SCAP and INSIG (Raghow et al., 2008). Insulin
increases the transcriptional activation potential of mature
SREBP-1c (Dif et al., 2006; Kotzka et al., 1998). Finally, insulin
also impedes the otherwise rapid degradation of the mature,
nuclear form of SREBP-1c (Raghow et al., 2008). In total, this
multiplicity of regulatory processes enables a robust induction
of SREBP-1c by insulin that is both rapid and sustained.
The principal regulatory point at which PASK acts appears
to be the proteolytic maturation of the precursor to mature
SREBP-1c. This is best evidenced by the decrease in the mature
form and increase in the precursor form observed in cells sub-
jected to PASK knockdown or inhibition. A specific decrease in
themature form is also observed in Pask/mice in the fed state.
We cannot eliminate the possibility, however, that PASK might
also regulate the synthesis or stability of the SREBF-1 mRNA.
We observed that Pask/ liver, PASK knockdown HepG2 cells,
and primary hepatocytes with PASK inhibition all had lower
SREBP-1c mRNA levels than the controls. However, this could
be explained by the fact that SREBP-1c positively regulates its
own gene expression (Amemiya-Kudo et al., 2000; Chen et al.,
2004). If the loss of PASK impairs the proteolytic activation of
SREBP-1c, this would secondarily lead to a decrease in the
SREBP-1c mRNA level. In fact, we found that PASK inhibition
decreased the activity of a luciferase reporter driven by the
SREBP-1c promoter in response to insulin, but this effect was
completely eliminated when the autoregulatory SREBP-binding
site within the promoter was mutated. It remains possible that
PASK acts at other steps to regulate SREBP-1c activity; never-
theless, our data do show that normal insulin-responsive matu-
ration requires PASK.
The mechanisms whereby insulin signaling promotes the
proteolytic activation of SREBP-1 are still incompletely under-
stood. It has been observed that Akt, in response to insulin
signaling, leads to the phosphorylation of SREBP-1c in amanner
that correlates with activation (Yellaturu et al., 2009a). Although
the functional significance of this SREBP-1c phosphorylation
has not been established yet, it is possible that PASK might
directly phosphorylate SREBP-1c to promote its maturation.
More recent work has shown that insulin signals through both
mTORC1-dependent and mTORC1-independent pathways to
promote SREBP-1 activation (Wan et al., 2011; Yecies et al.,
2011). The latter involves the regulation of INSIG2a, which is a
negative regulator of SREBP-1 (Yecies et al., 2011; Yellaturu
et al., 2009b). PASK does not appear to act through this mech-(E–G) Rat primary hepatocytes were treated with vehicle or BioE-1197 as in (D),
genes was measured as in Figure 1I. Data shown are the average of n = 3 ± SEM
(H) Rat primary hepatocytes were treated and measured for 14C-acetate incorpo
See also Figure S3.anism, since INSIG2 mRNA is not higher upon PASK knock-
down, as would be expected if this were the explanation for
impaired SREBP-1 processing. In fact, the INSIG2 mRNA is
lower upon PASK knockdown, perhaps as a compensatory
effect in response to impaired SREBP-1 activation.
The proteins and mechanisms that connect mTORC1 activa-
tion with stimulation of SREBP-1 processing are currently un-
known. Our data demonstrate that PASK is not required for Akt
or mTORC1 activation in response to insulin signaling, which
leads us to conclude that PASK acts either downstream of
mTORC1 or in a parallel pathway to promote SREBP-1 acti-
vation. The precise placement of PASK in this signaling network
and definition of the mechanisms that connect the nodes of this
network await further studies.
Not only did administration of the PASK inhibitor cause pro-
found decreases in the hepatic expression of SREBP-1c target
genes and the generation of mature SREBP-1, it also impacted
hepatic and systemic metabolic parameters. Both hepatic and
serum triglycerides were normalized, which might be expected
based on the suppression of lipogenic gene expression in the
liver. In addition, we observed a significant decrease in serum
glucose in HFrD-fed rats treated with the PASK inhibitor for
7 days, and in HbA1c in rats treated for either 45 or 90 days. In
conjunctionwith themodestdecrease in serum insulin, this is sug-
gestive of enhanced insulin sensitivity in inhibitor-treatedanimals.
A pathological vicious cycle has been described wherein the
hypoglycemic effects of insulin are blunted, but insulin maintains
the ability to activate SREBP-1c and lipogenesis (Biddinger
et al., 2008; Brown and Goldstein, 2008). Enhanced lipogenesis
and the increasingly dyslipidemic state exacerbate the ‘‘selec-
tive insulin resistance,’’ causing more insulin release. We hypo-
thesize that PASK inhibition prevents this vicious cycle by
mitigating the toxic lipogenesis that can occur under conditions
of insulin resistance and hyperinsulinemia. We previously
showed that Pask/ mice exhibit improved insulin sensitivity
and resistance to hepatic steatosis elicited by an HFD (Hao
et al., 2007). We now also show that treatment of HFrD-fed
rats with a PASK inhibitor completely normalized their elevated
expression of SREBP-1c target genes and hypertriglyceridemia.
Importantly, we observed no overt toxicity upon genetic
depletion of PASK (Pask/ mice) or upon extended treatment
with PASK inhibitor doses that were 10- to 30-fold higher than
those required to elicit significant effects on lipogenic gene
expression and serum triglycerides. This treatment regimen
had no effect on body weight, even after 90 days of treatment.
It also had no effect on the expression of SREBP-1c or its target
genes in two other tissues of metabolic importance, skeletal
muscle, and adipose tissue. In contrast, inhibition of mTORC1
with rapamycin caused decreased lipogenesis in adipose tissue,
which was accompanied by decreased expression of SREBP-1
(Pereira et al., 2013). The selectivity of the effect of PASK inhibi-
tion is also in contrast to the phenotype observed for themajority
of mice lacking SREBP-1, which die in utero (Shimano et al.,followed by insulin as in Figure 1I, and the mRNA abundance of the indicated
. The value of the vehicle-treated/unstimulated group was set as one.
ration into lipids as in (D). Data shown are the average of n = 3 ± SD.
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Figure 6. PASK Inhibition Decreases SREBP-1 Activity, Triglycerides, and Insulin Resistance in Animal Models
(A) Rats fed either an NCD or HFrD for 2 weeks were subjected to a once/day treatment with vehicle or the indicated dose of BioE-1115 by oral gavage for 1 week.
Following this regimen, the rats were fasted for 24 hr and then refed for 12 hr. Livers were harvested and qRT-PCR was performed for the indicated genes and
normalized to Cyclophilin A (n = 10/group). Data shown are the average ± SEM.
(B) Rats were maintained on an HF-HFrD for 18 weeks and treated with vehicle or the indicated dose of BioE-1115 as in (A) for the last 3 weeks. Livers were
harvested after rats were subjected to fast/refeeding as in (A). Whole-liver lysates and nuclear extracts were subjected to immunoblot to determine the abun-
dance of the precursor or mature form of SREBP-1 and the indicated control proteins. mpk: mg/kg.
(C) Triglycerides were measured in livers from the indicated treatment groups as described in (A) (n = 10/group).
(D–G) Serum TAG, cholesterol, glucose, and insulin were measured in animals treated as in (A).
(H) Calculated HOMA-IR values.
(I and J) Liver (I) and body (J) weights of the animals in (A). All data shown are the average ± SEM. See also Figures S4–S6.1997b), whereas mice lacking PASK are viable. Therefore, we
conclude that PASK is not required for the basal activation of
SREBP-1 or for the activation of SREBP-1 in all tissues. Our
data suggest an important role for PASK in the hepatic activation
of SREBP-1c in response to feeding. However, it is possible that
PASK has functions in other tissue types that may contribute to
the beneficial effect on metabolism we observed upon PASK252 Cell Reports 8, 242–255, July 10, 2014 ª2014 The Authorsinhibition. Nonetheless, this observation is of particular interest
in light of the potentially causal role that hepatic SREBP-1c
activation has been proposed to play in metabolic disease in
humans. Others have shown that genetic or pharmacological in-
hibition of SREBP maturation improves hepatic and whole-body
metabolism (Moon et al., 2012; Tang et al., 2011). We therefore
propose that SREBP-1c activation by PASK is an important
feature of the mammalian metabolic syndrome and should be
explored as a therapeutic opportunity in humans.
EXPERIMENTAL PROCEDURES
Animals
Pask/mice were described previously (Hao et al., 2007). Age-matched male
WT and Pask/ mice were maintained on either an NCD for 12 weeks or a
60% HFD for 8 weeks, from 8 to 10 weeks of age (60% fat by calories;
Research Diets). For fasting-refeeding studies, mice were either fasted for
24 hr or fasted for 24 hr and refed an NCD or HFD for the indicated time periods
before they were euthanized and their organs were harvested. All procedures
were approved by the Institutional Animal Care and Use Committee of the
University of Utah.
SDmale rats (Charles River Laboratories) were maintained on an HFrD (60%
fructose; Research Diets) or NCD for 2 weeks or on a high-fat and high-fruc-
tose diet (HF-HFrD, 60% high fat diet and 15% fructose drinking water) for
15 weeks before experiments were conducted. The rats were housed under
standard vivarium conditions (12 hr light/dark cycle) with water and chow ad
libitum. All studies were approved by the Institutional Animal Care and Use
Committee of the University of Utah and/or St. Louis University as appropriate.
Luciferase Assay
HepG2 cells were cotransfected with (1) pGPAT-Luc, pSCD-Luc, or pSRE-
Luc; (2) a construct expressing CMV-driven Renilla luciferase (Promega); or
(3) a pQCXIN-GFP, pcDNA3.1-2xFlag-mSREBP-1a, or pQCXIN-3xFlag-
pSREBP-1a construct, as indicated, using Lipofectamine LTX (Invitrogen),
according to the manufacturer’s instructions. Rat primary hepatocytes were
cotransfected with WT or mutant pSREBP-1c-Luc and Renilla luciferase using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
After transfection, the cells were serum-starved overnight, with additional
treatment of (1) vehicle, BioE-1197, or BioE-1428 and/or (2) 100 nM insulin
for 6 or 12 hr before harvest, as indicated. Firefly and Renilla luciferase were
assayed using the Dual-Reporter Luciferase Assay System (Promega).
Measurement of De Novo Lipogenesis
HepG2 cells or rat primary hepatocytes were treated with vehicle or 10 mM
BioE-1197 in serum-free media overnight. The next day, the cells were trans-
ferred to new media with vehicle or 30 mM BioE-1197 and 100 nM insulin for
6 hr as indicated, and were labeled with 10 mCi/ml [1-14C]-acetate (Perkin
Elmer) for the last 4 hr before harvest. The cells were washed twice with
PBS and then lysed in 0.5% Triton X-100. The lipid fraction was extracted
by adding chloroform andmethanol (v/v 2:1) followed by dH2O, with vortexing.
Samples were then centrifuged at 1,500 rpm for 15 min and the organic
(bottom) phase containing lipids was used to measure 14C incorporation on
a Beckman LS 6500 scintillation counter. The results were normalized to pro-
tein concentration of lysates.
ELISA
HEK293T cells were transfected with a pcDNA3.1-Flag-PASK (WT or kinase-
dead) construct using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. After 18 hr, the cells were reseeded into 96-well
plates in Dulbecco’s modified Eagle’s medium/1% fetal bovine serum. The
cells were then treated with DMSO or drug for 16 hr, followed by lysis in
0.2 ml lysis buffer (20 mM Na2HPO4, 0.5% Triton, 0.1% SDS, 0.02% azide,
1 mM NaF, 1 mM glycerophosphate, 1 mM Na3VO4). The lysates were then
applied to a MaxiSorb 96-well plate (Nunc) that was previously coated with
a-FLAG capture antibody (M2; Sigma), and blocked with 3% BSA (in 13
PBS). After incubation at 4C for 1.5 hr, the plates were washed with high-
salt washing buffer (20 mM Na2HPO4, 0.5% Triton X-100, 0.1% SDS, 0.02%
NaN3, 0.1% BSA, and 1 M NaCl) followed by low-salt buffer (150 mM NaCl).
Then the plates were incubated for 2 hr with antibody to either phospho-Akt
substrate (9614; Cell Signaling) or hPASK (U2501), followed by high- and
low-salt buffer washes. Subsequently, the plates were incubated with horse-
radish peroxidase-conjugated secondary antibody for 1 hr and then washed
with high- and low-salt buffer and 13 PBS. The phospho-AKT substrate orPASK antibody-dependent luminescence signal was assayed using the
LumiGLO chemiluminescent substrate system (KPL) according to the manu-
facturer’s instructions. The inhibition curve and IC50 were determined using
Prism software (GraphPad).
Chemicals and Dosing Formulations
BioE-1197, BioE-1428, and BioE-1115 were synthesized by Pharmaron. All
compounds were made up in a vehicle formulation of 0.5% methylcellulose
and 0.025% Tween-80 (Sigma) in ddH20. Dosages were calculated and
compounds were weighed and placed in a 15 ml glass homogenizer (Kimble
Chase) towhich vehiclewas added. The compoundswere ground to a fine sus-
pensionand transferred to ascrew-top tube.Thehomogenizerwas rinsed twice
with vehicle and then brought to the final volume. Compounds were made up
every 4–5 days based on the animals’ weight and stored at room temperature.
The animals were orally dosed once a day between 7 a.m. and 9 a.m.
BioE-1115 in the SD Diet-Induced Obesity Model
Male SD rats (n = 8–12) were obtained in this study with an average weight of
129.4 ± 0.63 g and were maintained on an HFrD for 2 weeks or on an HF-HFrD
for 15 weeks prior to experimentation. The rats were dosed by oral gavage
once a day for 7, 21, or 90 days at doses of 1, 3, 10, 30, and 100 mg/kg of
BioE-1115 or with vehicle. Body weights were taken every day for compound
formulation. The animals were fasted for 24 hr and refed for 12 hr prior to termi-
nation of the experiment. All animals received their respective compound
dosage 3 hr prior to termination. The animals were euthanized by CO2 asphyx-
iation, and cardiac puncture was performed for the final serum analysis. Liver
tissue was taken during necropsy, weighed, and snap-frozen in liquid N2.
Blood was centrifuged at 3,500 rpm for 10 min and serum was collected and
analyzed for insulin, glucose, cholesterol, and triglycerides using a Beckman
CX 5Pro (Beckman Coulter).
Statistical Analysis
Data are presented as mean ± SD unless otherwise indicated. A two-tailed
equal variance t test was used to compare differences and the null hypothesis
was rejected at the 0.05 level.
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